BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-01-10
Target enrollment:
Participant gender:
Summary
Phase Ib / II study to determine the Maximum Tolerated Dose and Recommended Phase II Dose,
and to evaluate the safety and antitumour activity, of BI 836845 and everolimus in
combination with exemestane in women with HR+/HER2- advanced breast cancer